BioCryst (BO1) Financial Statements
BioCryst Financial Overview
BioCryst's market cap is currently $1.93B. The company's EPS TTM is $-1.44; its P/E ratio is -5.89; BioCryst is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $0.08. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 874.84M | $ 450.71M | $ 331.41M | $ 270.83M | $ 157.17M |
| Gross Profit | $ 855.76M | $ 438.23M | $ 326.75M | $ 264.23M | $ 149.91M |
| Operating Income | $ 340.99M | $ -2.54M | $ -103.71M | $ -148.44M | $ -177.72M |
| EBITDA | $ 347.65M | $ 12.81M | $ -116.33M | $ -143.85M | $ -121.74M |
| Net Income | $ 263.86M | $ -88.88M | $ -226.54M | $ -247.12M | $ -184.06M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 274.75M | $ 321.06M | $ 388.99M | $ 424.31M | $ 507.60M |
| Total Assets | $ 514.16M | $ 490.42M | $ 516.96M | $ 550.00M | $ 588.15M |
| Total Debt | $ 438.87M | $ 841.42M | $ 825.15M | $ 741.45M | $ 593.24M |
| Net Debt | $ 349.14M | $ 736.50M | $ 714.50M | $ 436.69M | $ 88.85M |
| Total Liabilities | $ 633.31M | $ 966.35M | $ 972.49M | $ 844.60M | $ 695.14M |
| Stockholders' Equity | $ -119.15M | $ -475.93M | $ -455.53M | $ -294.60M | $ -106.99M |
| Cash Flow | |||||
| Free Cash Flow | $ 327.41M | $ -53.14M | $ -97.31M | $ -163.20M | $ -144.54M |
| Operating Cash Flow | $ 329.88M | $ -52.02M | $ -95.14M | $ -161.85M | $ -142.16M |
| Investing Cash Flow | $ -13.69M | $ 52.59M | $ -131.50M | $ -128.24M | $ 15.80M |
| Financing Cash Flow | $ -332.44M | $ -5.76M | $ 32.48M | $ 88.03M | $ 359.67M |
Currency in USD